Johnson & Johnson and Procter & Gamble are both Dividend Kings with similar valuations, but Johnson & Johnson is favored for long-term dividend growth due to better dividend coverage, lower payout ratio, and stronger growth prospects despite P&G's longer dividend history and higher yield. J&J’s diversified product growth and lower structural risks position it to raise dividends more sustainably over 20 years. Investors should watch J&J’s litigation costs and upcoming business changes, but its recent performance and management guidance suggest a stronger dividend profile than P&G for long-term retirees.
Johnson & Johnson trades at USD 253.93 with a 0.40% gain as of Oct 06, 2026 18:44 WIB on Pluang. Procter & Gamble is priced at USD 147.92, up 1.36% at the same time. Despite P&G's higher dividend yield of 2.98%, J&J's market cap of $609.54B is nearly double P&G's $338.97B, showing stronger market confidence in J&J's growth prospects.
Johnson & Johnson announced two-year Phase 3 data for ICOTYDE (icotrokinra), an oral peptide targeting IL-23 receptor, showing sustained skin clearance in patients with moderate-to-severe plaque psoriasis, especially in sensitive areas like scalp and...
In 2026, both Johnson & Johnson (J&J) and Merck have seen strong stock gains, but J&J's dividend appears more secure for retirement investors. J&J has a consistent history of annual dividend raises, strong free cash flow, and has already faced its ma...
